dsm-firmenich

9 May 2023

DSM and Firmenich jointly announced that Firmenich is now a wholly owned subsidiary of DSM-Firmenich AG. This transaction completes the merger of equals between DSM and Firmenich.

The press release can be accessed here. 

4 May 2023

DSM-Firmenich AG announced an evolution in the company’s CEO structure ahead of the completion of its merger of equals between DSM and Firmenich.

The press release can be accessed here. 

1 May 2023

DSM and Firmenich jointly announced that the Exchange Offer that launched on 22 November 2022 has successfully closed following the end of the Post-Closing Acceptance Period. As a result, the termination of the listing and trading of DSM ordinary shares on Euronext Amsterdam will commence shortly.

The press release can be accessed here. 

17 Apr 2023 

DSM and Firmenich jointly announce that the Exchange Offer to DSM shareholders is unconditional and all transaction conditions have been satisfied or waived. As a result, trading in dsm-firmenich shares on Euronext Amsterdam will commence on 18 April 2023 ahead of the contribution of the Firmenich business on 8 May 2023.

DSM shareholders who have not yet tendered their DSM shares have the opportunity to do so under the same terms and conditions as applicable to the exchange offer until 28 April 2023 at 17:40 hours CEST.

The press release can be found on the transaction website here. 

6 Apr 2023 

DSM and Firmenich published a supplement to the offering circular dated 22 November 2022.

The supplement can be found on the transaction website here. 

4 Apr 2023 

DSM and Firmenich confirm that they have obtained competition clearance from the Competition Commission of India (CCI) and now have competition clearance in all required jurisdictions. DSM shareholders have until 17:40 CEST on 17 April 2023 to tender their shares.

The press release and more information about the exchange offer to DSM shareholders can be accessed here. 

31 Mar 2023 

DSM and Firmenich confirm that the acceptance period during which DSM shareholders can tender their shares as part of the Exchange Offer that launched on 22 November 2022, has been extended. The reason for this extension is that the last competition clearance remains which, while it is taking some more time, the decision is expected to be forthcoming.

The press release can be accessed here. 

23 Feb 2023 

DSM and Firmenich jointly announce that they have obtained the unconditional competition clearance from the European Commission on 22 February 2023. This follows the unconditional competition clearance of China’s State Administration for Market Regulation (SAMR) received on 16 February 2023. Consequently, competition clearance has been obtained in nine out of the ten jurisdictions required to satisfy the offer condition relating to competition clearances.

The press release can be accessed here. 

23 Jan 2023 

An EGM was held on Monday 23 January 2023 at which DSM shareholders voted to approve, amongst other things, the transactions that will result in a new, dynamic creation and innovation partner in nutrition, beauty and well-being; DSM-Firmenich AG.

More information for DSM shareholders can be found here.

23 Jan 2023 

DSM and Firmenich confirm that the acceptance period during which DSM shareholders can tender their shares as part of the Exchange Offer that launched on 22 November 2022, has been extended. The reason for this extension is that not all competition clearances will be obtained by 31 January 2023 although, to date, no substantive competition concerns have been identified.

The press release can be accessed here. 

22 Nov 2022

DSM and Firmenich jointly announced the launch of the exchange offer to DSM shareholders as part of the merger of equals to create DSM-Firmenich AG. 

More information for DSM shareholders can be found here.

The press release and associated information, including the recording of a presentation and Q&A with analysts and investors, can be accessed here.

28 Jun 2022

Pursuant to Section 7, paragraph 1 sub a of the Netherlands Decree on Public Takeover Bids (Besluit openbare biedingen Wft), which requires a public announcement containing a status update on an intended public offer within four weeks after its initial public announcement, DSM and Firmenich confirm that they are making good progress on the preparations for the Offer.

The press release can be accessed here. 

13 Jun 2022

DSM and Firmenich hosted a joint Capital Markets Day for institutional investors and equity analysts, to provide a deeper understanding of Firmenich’s businesses and to present DSM-Firmenich AG, outlining its key value drivers, demonstrating how the complementary nature of the companies can enable enhanced innovation and co-creation with their customers, and through this, increase returns and deliver long-term sustainable growth and shareholder value.

Held at the Palais Brongniart, the historical Paris stock exchange, the recording of the presentations and the Q&A session is available to be watched back here.

13 Jun 2022

DSM and Firmenich jointly announced the future leadership team for DSM-Firmenich AG. The Executive Committee will have a balanced team of talented individuals drawn from both DSM and Firmenich and representing the diversity, skillset, and ambitions of the combined company.

The press release can be accessed here. 

31 May 2022

DSM and Firmenich announced an intention to merge to become the leading creation and innovation partner in nutrition, beauty and well-being. The combination will bring together Firmenich’s unique leading Perfumery and Taste businesses, its world-class science platforms and associated co-creation capabilities with DSM’s outstanding Health and Nutrition portfolio and renowned scientific expertise.

The press release can be accessed here.